Literature DB >> 11801472

Cladribine (2-chlorodeoxyadenosine) therapy in hairy cell leukemia variant. A report of three cases.

Luis Palomera1, José Ma Domingo, Carlos Sola, Gemma Azaceta, María Teresa Calvo, Martin Gutierrez.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11801472

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  8 in total

Review 1.  Hairy cell leukemia: present and future directions.

Authors:  Robert J Kreitman
Journal:  Leuk Lymphoma       Date:  2019-05-09

2.  Purine nucleoside analogs plus rituximab are an effective treatment choice for hairy cell leukemia-variant.

Authors:  Yi Wang; Tingyu Wang; Ying Yu; Qi Wang; Yuting Yan; Ru Li; Qi Sun; Wenjie Xiong; Rui Lyu; Zhen Yu; Wei Liu; Weiwei Sui; Wenyang Huang; Huijun Wang; Chengwen Li; Jun Wang; Dehui Zou; Gang An; Jianxiang Wang; Lugui Qiu; Shuhua Yi
Journal:  Ann Hematol       Date:  2022-04-18       Impact factor: 3.673

Review 3.  Hairy cell leukemia-new genes, new targets.

Authors:  Robert J Kreitman
Journal:  Curr Hematol Malig Rep       Date:  2013-09       Impact factor: 3.952

4.  Cladribine with immediate rituximab for the treatment of patients with variant hairy cell leukemia.

Authors:  Robert J Kreitman; Wyndham Wilson; Katherine R Calvo; Evgeny Arons; Laura Roth; Jeffrey Sapolsky; Hong Zhou; Mark Raffeld; Maryalice Stetler-Stevenson
Journal:  Clin Cancer Res       Date:  2013-11-25       Impact factor: 12.531

5.  Hairy cell leukemia variant: the importance of differential diagnosis.

Authors:  Renata Cristina Messores Rudolf-Oliveira; Mayara Marin Pirolli; Fernanda Santos de Souza; Juliana Michels; Maria Cláudia Santos-Silva
Journal:  Rev Bras Hematol Hemoter       Date:  2015-02-11

6.  Long-term follow-up after rituximab plus bendamustine in a patient with relapsed or refractory hairy cell leukemia variant: A case report.

Authors:  Naoto Imoto; Daisuke Koyama; Isamu Sugiura; Shingo Kurahashi
Journal:  Medicine (Baltimore)       Date:  2021-02-05       Impact factor: 1.817

Review 7.  Current and Emerging Therapeutic Options for Hairy Cell Leukemia Variant.

Authors:  Qiuying Liu; Nicholas Harris; Narendranath Epperla; Leslie A Andritsos
Journal:  Onco Targets Ther       Date:  2021-03-09       Impact factor: 4.147

8.  Long term follow-up of a phase II study of cladribine with concurrent rituximab with hairy cell leukemia variant.

Authors:  Dai Chihara; Evgeny Arons; Maryalice Stetler-Stevenson; Constance Yuan; Hao-Wei Wang; Hong Zhou; Mark Raffeld; Liqiang Xi; Seth M Steinberg; Julie Feurtado; Lacey James-Echenique; Chin-Hsien Tai; Keyur P Patel; Raul C Braylan; Katherine R Calvo; Irina Maric; Alina Dulau-Florea; Robert J Kreitman
Journal:  Blood Adv       Date:  2021-12-14
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.